Shares of Portage Biotech Inc. more than doubled in after-hours trading on Thursday as the company reported promising ...

Recent findings suggest that mitochondrial-targeted therapy, either by reducing reactive oxygen species production or ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Glioblastoma has remained one of the toughest cancers to treat, but new research suggests that suppressing a protein (ZNF638) ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...

For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, ...

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine ...